CDMO leader Cambrex initiates a $120 million expansion in Charles City, Iowa, marking a significant capital investment to scale production capabilities and meet rising global demand.
Cambrex is significantly scaling its operational footprint by initiating a $120 million expansion project at its Charles City, Iowa facility. This capital investment underscores the company's commitment to increasing its CDMO capacity to meet global demand for pharmaceutical development and manufacturing services.
Cambrex is investing $120 million into the expansion of its Charles City, Iowa site.
Cambrex is a global contract development and manufacturing organization (CDMO) for the pharmaceutical industry.
Cambrex has officially commenced construction on a $120 million expansion project at its Charles City, Iowa facility. This strategic investment aims to bolster the company's global manufacturing capacity and service offerings as a leading contract development and manufacturing organization (CDMO).
The $120 million investment is designed to expand the company's manufacturing capacity and enhance its service offerings as a global contract development and manufacturing organization.